Exact Mass: 329.248

Exact Mass Matches: 329.248

Found 314 metabolites which its exact mass value is equals to given mass value 329.248, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Trilostane

(1S,2R,6R,8S,11S,12S,15S,16S)-5,15-dihydroxy-2,16-dimethyl-7-oxapentacyclo[9.7.0.0²,⁸.0⁶,⁸.0¹²,¹⁶]octadec-4-ene-4-carbonitrile

C20H27NO3 (329.1991)


Trilostane is only found in individuals that have used or taken this drug. It is an inhibitor of 3 beta-hydroxysteroid dehydrogenase used in the treatment of Cushings syndrome. It was withdrawn from the United States market in April 1994. [Wikipedia]Trilostane produces suppression of the adrenal cortex by inhibiting enzymatic conversion of steroids by 3-beta-hydroxysteroid dehydrogenase/delta 5,4 ketosteroid isomerase, thus blocking synthesis of adrenal steroids. H - Systemic hormonal preparations, excl. sex hormones and insulins > H02 - Corticosteroids for systemic use > H02C - Antiadrenal preparations > H02CA - Anticorticosteroids C471 - Enzyme Inhibitor > C54678 - Hydroxysteroid Dehydrogenase Inhibitor > C2184 - 3-Hydroxysteroid Dehydrogenase Inhibitor C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C274 - Antineoplastic Agent > C129818 - Antineoplastic Hormonal/Endocrine Agent > C481 - Antiestrogen C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C1740 - Aromatase Inhibitor D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist > C2355 - Anti-Adrenal D012102 - Reproductive Control Agents > D000019 - Abortifacient Agents C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor D000970 - Antineoplastic Agents D004791 - Enzyme Inhibitors Same as: D01180

   

Splendor

Tralkoxydim

C20H27NO3 (329.1991)


   

HETISINE

Hetisan-2,11,13-triol

C20H27NO3 (329.1991)


Annotation level-1

   

Homoormosanine

(7alpha,9alpha,11alpha,16beta,18beta)-Homoormosanine

C21H35N3 (329.2831)


   

MLS002608110

4-Methyl-4-aza-5-pregnene-3,20-dione

C21H31NO2 (329.2355)


   

17beta-Acetamidoandrost-4-en-3-one

n-(3-oxoandrost-4-en-17-yl)acetamide

C21H31NO2 (329.2355)


   

Pipertipine

(7E)-8-(2H-1,3-benzodioxol-5-yl)-1-(piperidin-1-yl)oct-7-en-1-one

C20H27NO3 (329.1991)


Pipertipine is found in herbs and spices. Pipertipine is an alkaloid from the dried seeds of pepper Piper nigrum. Alkaloid from the dried seeds of pepper Piper nigrum. Pipertipine is found in herbs and spices.

   

(8E)-Piperamide-C9:1

(8Z)-9-(2H-1,3-benzodioxol-5-yl)-1-(pyrrolidin-1-yl)non-8-en-1-one

C20H27NO3 (329.1991)


(8E)-Piperamide-C9:1 is found in herbs and spices. (8E)-Piperamide-C9:1 is a constituent of pepper (Piper nigrum). Constituent of pepper (Piper nigrum). (8E)-Piperamide-C9:1 is found in herbs and spices.

   

Retrofractamide C

(2E,8E)-9-(2H-1,3-Benzodioxol-5-yl)-N-(2-methylpropyl)nona-2,8-dienimidate

C20H27NO3 (329.1991)


Retrofractamide C is an alkaloid from Piper retrofractum (Javanese long pepper). Alkaloid from Piper retrofractum (Javanese long pepper).

   

Dihydroceramide

N-[(2S,3R)-1,3-Dihydroxyoctadecan-2-yl]formamide

C19H39NO3 (329.293)


Dihydroceramide is an intermediate in sphingolipid metabolism. Dihydroceramide is the third to last step in the synthesis of beta-D-Galactosyl-1,4-beta-D glucosylceramide and is converted from sphinganine via the enzyme acyl-CoA-dependent ceramide synthase (EC 2.3.1.24). It is then converted to N-acylsphingosine via the enzyme fatty acid desaturase (EC 1.14.-.-). [HMDB] Dihydroceramide is an intermediate in sphingolipid metabolism. Dihydroceramide is the third to last step in the synthesis of beta-D-Galactosyl-1,4-beta-D glucosylceramide and is converted from sphinganine via the enzyme acyl-CoA-dependent ceramide synthase (EC 2.3.1.24). It is then converted to N-acylsphingosine via the enzyme fatty acid desaturase (EC 1.14.-.-).

   

Palmitoyl Serinol

N-[2-Hydroxy-1-(hydroxymethyl)ethyl]-hexadecanamide

C19H39NO3 (329.293)


2-Palmitoyl glycerol (2-PG) has been isolated along with the potent endocannabinoid 2-arachidonoyl glycerol (2-AG) from various tissues.1 Although 2-PG displays no intrinsic agonist activity on CB1 or CB2 receptors, it does potentiate the ability of 2-AG to inhibit adenylyl cyclase. 2-PG also potentiates the analgesic, hypokinetic, and anxiolytic effects of 2-AG in mice. This ?entourage? effect has been attributed to the ability of compounds such as 2-PG to inhibit reuptake and/or compete with the active endocannabinoids for access to inactivating enzymes such as FAAH and monoglyceride lipase.2,3 Palmitoyl serinol is a stable analog of 2-PG bearing an amide linkage in place of the labile glyceryl ester. This has the potential to enhance its ?entourage? activities as a result of a prolonged in vivo half-life. Palmitoyl serinol is also an analog of C-16 ceramide. Incubation of neuroblastoma cells with palmitoyl serinol causes apoptosis with an IC50 of approximately 80 ?M. [HMDB] 2-Palmitoyl glycerol (2-PG) has been isolated along with the potent endocannabinoid 2-arachidonoyl glycerol (2-AG) from various tissues.1 Although 2-PG displays no intrinsic agonist activity on CB1 or CB2 receptors, it does potentiate the ability of 2-AG to inhibit adenylyl cyclase. 2-PG also potentiates the analgesic, hypokinetic, and anxiolytic effects of 2-AG in mice. This "entourage" effect has been attributed to the ability of compounds such as 2-PG to inhibit reuptake and/or compete with the active endocannabinoids for access to inactivating enzymes such as FAAH and monoglyceride lipase.2,3 Palmitoyl serinol is a stable analog of 2-PG bearing an amide linkage in place of the labile glyceryl ester. This has the potential to enhance its "entourage" activities as a result of a prolonged in vivo half-life. Palmitoyl serinol is also an analog of C-16 ceramide. Incubation of neuroblastoma cells with palmitoyl serinol causes apoptosis with an IC50 of approximately 80 µM.

   

4,8 Dimethylnonanoyl carnitine

3-[(4,8-dimethylnonanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C18H35NO4 (329.2566)


4,8 dimethylnonanoyl carnitine is an intermediate in phytanic and pristanic acid metabolism. Both phytanic acid and pristanic acid are initially oxidized in peroxisomes to 4,8-dimethylnonanoyl-CoA, which is then converted to to 4,8-dimethylnonanoyl carnitine (presumably by peroxisomal carnitine octanoyltransferase), and exported to the mitochondrion. After transport across the mitochondrial membrane and transfer of the acylgroup to coenzyme A, further oxidation to 2,6-dimethylheptanoyl-CoA occurs (PMID: 9469587). 4,8 dimethylnonanoyl carnitine is not a substrate for carnitine acetyltransferase, another acyltransferase localized in peroxisomes, which catalyzes the formation of carnitine esters of the other products of pristanic acid beta-oxidation, namely acetyl-CoA and propionyl-CoA. (PMID: 10486279). Earlier studies have shown that pristanic acid undergoes three cycles of beta-oxidation in peroxisomes to produce 4,8-dimethylnonanoyl-CoA (DMN-CoA) which is then transported to the mitochondria for full oxidation to CO(2) and H(2)O. In principle, this can be done via two different mechanisms in which DMN-CoA is either converted into the corresponding carnitine ester or hydrolyzed to 4,8-dimethylnonanoic acid plus CoASH.(PMID: 11785945). Phytanic acid (3,7,11,15-tetramethylhexadecanoic acid) and pristanic acid (2,6,10,14-tetramethylpentadecanoic acid) are branched-chain fatty acids that are constituents of the human diet. As phytanic acid possesses a beta-methyl group, it cannot be degraded by beta-oxidation. Instead, phytanic acid is first degraded by alpha-oxidation, yielding pristanic acid, which is subsequently degraded by beta-oxidation. Phytanic acid alpha-oxidation is thought to occur partly, and pristanic acid beta-oxidation exclusively, in peroxisomes. Accumulation of phytanic acid and pristanic acid is found in blood and tissues of patients affected with generalized peroxisomal disorders. [HMDB] 4,8 dimethylnonanoyl carnitine is an intermediate in phytanic and pristanic acid metabolism. Both phytanic acid and pristanic acid are initially oxidized in peroxisomes to 4,8-dimethylnonanoyl-CoA, which is then converted to to 4,8-dimethylnonanoyl carnitine (presumably by peroxisomal carnitine octanoyltransferase), and exported to the mitochondrion. After transport across the mitochondrial membrane and transfer of the acylgroup to coenzyme A, further oxidation to 2,6-dimethylheptanoyl-CoA occurs (PMID: 9469587). 4,8 dimethylnonanoyl carnitine is not a substrate for carnitine acetyltransferase, another acyltransferase localized in peroxisomes, which catalyzes the formation of carnitine esters of the other products of pristanic acid beta-oxidation, namely acetyl-CoA and propionyl-CoA. (PMID: 10486279). Earlier studies have shown that pristanic acid undergoes three cycles of beta-oxidation in peroxisomes to produce 4,8-dimethylnonanoyl-CoA (DMN-CoA) which is then transported to the mitochondria for full oxidation to CO(2) and H(2)O. In principle, this can be done via two different mechanisms in which DMN-CoA is either converted into the corresponding carnitine ester or hydrolyzed to 4,8-dimethylnonanoic acid plus CoASH.(PMID: 11785945). Phytanic acid (3,7,11,15-tetramethylhexadecanoic acid) and pristanic acid (2,6,10,14-tetramethylpentadecanoic acid) are branched-chain fatty acids that are constituents of the human diet. As phytanic acid possesses a beta-methyl group, it cannot be degraded by beta-oxidation. Instead, phytanic acid is first degraded by alpha-oxidation, yielding pristanic acid, which is subsequently degraded by beta-oxidation. Phytanic acid alpha-oxidation is thought to occur partly, and pristanic acid beta-oxidation exclusively, in peroxisomes. Accumulation of phytanic acid and pristanic acid is found in blood and tissues of patients affected with generalized peroxisomal disorders.

   

6-Keto-decanoylcarnitine

3-[(6-oxodecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C17H31NO5 (329.2202)


6-Keto-decanoylcarnitine is an acylcarnitine. More specifically, it is an 6-oxodecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy.  This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 6-Keto-decanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 6-keto-decanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews]. A human metabolite taken as a putative food compound of mammalian origin [HMDB]

   

Undecanoylcarnitine

4-(trimethylazaniumyl)-3-(undecanoyloxy)butanoate

C18H35NO4 (329.2566)


Undecanoylcarnitine is an acylcarnitine. More specifically, it is an undecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy.  This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Undecanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine undecanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews]. A human metabolite taken as a putative food compound of mammalian origin [HMDB]

   

N-desethyloxybutynin

4-(ethylamino)but-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate

C20H27NO3 (329.1991)


N-desethyloxybutynin is a metabolite of oxybutynin. Oxybutynin (Ditropan, Lyrinel XL) is an anticholinergic medication used to relieve urinary and bladder difficulties, including frequent urination and inability to control urination, by decreasing muscle spasms of the bladder. It competitively antagonizes the M1, M2, and M3 subtypes of the muscarinic acetylcholine receptor. It also has direct spasmolytic effects on bladder smooth muscle as a calcium antagonist and local anesthetic, but at concentrations far above those used clinically. (Wikipedia) D000890 - Anti-Infective Agents > D000892 - Anti-Infective Agents, Urinary > D008333 - Mandelic Acids

   

5-Methyldecanoylcarnitine

3-[(5-methyldecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C18H35NO4 (329.2566)


5-Methyldecanoylcarnitine is an acylcarnitine. More specifically, it is an 5-methyldecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 5-Methyldecanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 5-Methyldecanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

4-Methyldecanoylcarnitine

3-[(4-methyldecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C18H35NO4 (329.2566)


4-Methyldecanoylcarnitine is an acylcarnitine. More specifically, it is an 4-methyldecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 4-Methyldecanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 4-Methyldecanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

6-Methyldecanoylcarnitine

3-[(6-methyldecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C18H35NO4 (329.2566)


6-Methyldecanoylcarnitine is an acylcarnitine. More specifically, it is an 6-methyldecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 6-Methyldecanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 6-Methyldecanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

8-Methyldecanoylcarnitine

3-[(8-methyldecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C18H35NO4 (329.2566)


8-Methyldecanoylcarnitine is an acylcarnitine. More specifically, it is an 8-methyldecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 8-Methyldecanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 8-Methyldecanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

7-Methyldecanoylcarnitine

3-[(7-methyldecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C18H35NO4 (329.2566)


7-Methyldecanoylcarnitine is an acylcarnitine. More specifically, it is an 7-methyldecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 7-Methyldecanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 7-Methyldecanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

3-Methyldecanoylcarnitine

3-[(3-methyldecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C18H35NO4 (329.2566)


3-Methyldecanoylcarnitine is an acylcarnitine. More specifically, it is an 3-methyldecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-Methyldecanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3-Methyldecanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

9-Methyldecanoylcarnitine

3-[(9-methyldecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C18H35NO4 (329.2566)


9-Methyldecanoylcarnitine is an acylcarnitine. More specifically, it is an 9-methyldecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 9-Methyldecanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 9-Methyldecanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

5-Hydroxydec-3-enoylcarnitine

3-[(5-hydroxydec-3-enoyl)oxy]-4-(trimethylazaniumyl)butanoate

C17H31NO5 (329.2202)


5-Hydroxydec-3-enoylcarnitine is an acylcarnitine. More specifically, it is an 5-hydroxydec-3-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 5-Hydroxydec-3-enoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 5-Hydroxydec-3-enoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

5-Hydroxydec-8-enoylcarnitine

3-[(5-hydroxydec-8-enoyl)oxy]-4-(trimethylazaniumyl)butanoate

C17H31NO5 (329.2202)


5-Hydroxydec-8-enoylcarnitine is an acylcarnitine. More specifically, it is an 5-hydroxydec-8-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 5-Hydroxydec-8-enoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 5-Hydroxydec-8-enoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

5-Hydroxydec-5-enoylcarnitine

3-[(5-hydroxydec-5-enoyl)oxy]-4-(trimethylazaniumyl)butanoate

C17H31NO5 (329.2202)


5-Hydroxydec-5-enoylcarnitine is an acylcarnitine. More specifically, it is an 5-hydroxydec-5-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 5-Hydroxydec-5-enoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 5-Hydroxydec-5-enoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

5-Hydroxydec-6-enoylcarnitine

3-[(5-hydroxydec-6-enoyl)oxy]-4-(trimethylazaniumyl)butanoate

C17H31NO5 (329.2202)


5-Hydroxydec-6-enoylcarnitine is an acylcarnitine. More specifically, it is an 5-hydroxydec-6-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 5-Hydroxydec-6-enoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 5-Hydroxydec-6-enoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

5-Hydroxydec-7-enoylcarnitine

3-[(5-hydroxydec-7-enoyl)oxy]-4-(trimethylazaniumyl)butanoate

C17H31NO5 (329.2202)


5-Hydroxydec-7-enoylcarnitine is an acylcarnitine. More specifically, it is an 5-hydroxydec-7-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 5-Hydroxydec-7-enoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 5-Hydroxydec-7-enoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

5-Hydroxydec-4-enoylcarnitine

3-[(5-hydroxydec-4-enoyl)oxy]-4-(trimethylazaniumyl)butanoate

C17H31NO5 (329.2202)


5-Hydroxydec-4-enoylcarnitine is an acylcarnitine. More specifically, it is an 5-hydroxydec-4-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 5-Hydroxydec-4-enoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 5-Hydroxydec-4-enoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(2Z)-5-Hydroxydec-2-enoylcarnitine

3-[(5-hydroxydec-2-enoyl)oxy]-4-(trimethylazaniumyl)butanoate

C17H31NO5 (329.2202)


(2Z)-5-Hydroxydec-2-enoylcarnitine is an acylcarnitine. More specifically, it is an (2Z)-5-hydroxydec-2-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (2Z)-5-Hydroxydec-2-enoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (2Z)-5-Hydroxydec-2-enoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

3-oxodecanoylcarnitine

3-[(3-oxodecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C17H31NO5 (329.2202)


3-oxodecanoylcarnitine is an acylcarnitine. More specifically, it is an 3-oxodecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-oxodecanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3-oxodecanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

9-Oxodecanoylcarnitine

3-[(9-oxodecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C17H31NO5 (329.2202)


9-Oxodecanoylcarnitine is an acylcarnitine. More specifically, it is an 9-oxodecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 9-Oxodecanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 9-Oxodecanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

7-Oxodecanoylcarnitine

3-[(7-oxodecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C17H31NO5 (329.2202)


7-Oxodecanoylcarnitine is an acylcarnitine. More specifically, it is an 7-oxodecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 7-Oxodecanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 7-Oxodecanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

5-Oxodecanoylcarnitine

3-[(5-oxodecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C17H31NO5 (329.2202)


5-Oxodecanoylcarnitine is an acylcarnitine. More specifically, it is an 5-oxodecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 5-Oxodecanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 5-Oxodecanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

4-Oxodecanoylcarnitine

3-[(4-oxodecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C17H31NO5 (329.2202)


4-Oxodecanoylcarnitine is an acylcarnitine. More specifically, it is an 4-oxodecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 4-Oxodecanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 4-Oxodecanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

8-Oxodecanoylcarnitine

3-[(8-oxodecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C17H31NO5 (329.2202)


8-Oxodecanoylcarnitine is an acylcarnitine. More specifically, it is an 8-oxodecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 8-Oxodecanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 8-Oxodecanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

N-Lauroyl Glutamic acid

2-dodecanamidopentanedioic acid

C17H31NO5 (329.2202)


N-lauroyl glutamic acid, also known as N-lauroyl glutamate belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is a Lauric acid amide of Glutamic acid. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Lauroyl Glutamic acid is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Lauroyl Glutamic acid is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.

   

N-Myristoyl Threonine

3-hydroxy-2-tetradecanamidobutanoic acid

C18H35NO4 (329.2566)


N-myristoyl threonine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is a Myristic acid amide of Threonine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Myristoyl Threonine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Myristoyl Threonine is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.

   

Modrastane

5,15-dihydroxy-2,16-dimethyl-7-oxapentacyclo[9.7.0.0^{2,8}.0^{6,8}.0^{12,16}]octadec-4-ene-4-carbonitrile

C20H27NO3 (329.1991)


   

Modrefen

15-hydroxy-2,16-dimethyl-5-oxo-7-oxapentacyclo[9.7.0.0^{2,8}.0^{6,8}.0^{12,16}]octadecane-4-carbonitrile

C20H27NO3 (329.1991)


   

Prenylamine

(3,3-diphenylpropyl)(1-phenylpropan-2-yl)amine

C24H27N (329.2143)


C - Cardiovascular system > C01 - Cardiac therapy > C01D - Vasodilators used in cardiac diseases C78274 - Agent Affecting Cardiovascular System > C29707 - Vasodilating Agent D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators

   

1-[(3-Phenyl-3-cyclohexenyl)methyl]-4-phenyl-1,2,3,6-tetrahydropyridine

4-phenyl-1-[(3-phenylcyclohex-3-en-1-yl)methyl]-1,2,3,6-tetrahydropyridine

C24H27N (329.2143)


   

8-trans-Piperamide-C-9-1

(8E)-9-(2H-1,3-benzodioxol-5-yl)-1-(pyrrolidin-1-yl)non-8-en-1-one

C20H27NO3 (329.1991)


8-trans-piperamide-c-9-1 is a member of the class of compounds known as benzodioxoles. Benzodioxoles are organic compounds containing a benzene ring fused to either isomers of dioxole. Dioxole is a five-membered unsaturated ring of two oxygen atoms and three carbon atoms. 8-trans-piperamide-c-9-1 is practically insoluble (in water) and an extremely weak basic (essentially neutral) compound (based on its pKa). 8-trans-piperamide-c-9-1 can be found in pepper (spice), which makes 8-trans-piperamide-c-9-1 a potential biomarker for the consumption of this food product.

   

all-cis-7,10,13,16,19-docosapentaenoate

(7Z,10Z,16Z,19Z)-Docosa-7,10,13,16,19-pentaenoic acid

C22H33O2 (329.248)


All-cis-7,10,13,16,19-docosapentaenoate, also known as N-3 docosapentaenoic acid or c22:5(omega-3)(1-), is a member of the class of compounds known as very long-chain fatty acids. Very long-chain fatty acids are fatty acids with an aliphatic tail that contains at least 22 carbon atoms. All-cis-7,10,13,16,19-docosapentaenoate is practically insoluble (in water) and a weakly acidic compound (based on its pKa). All-cis-7,10,13,16,19-docosapentaenoate can be found in a number of food items such as grapefruit/pummelo hybrid, chia, capers, and muscadine grape, which makes all-cis-7,10,13,16,19-docosapentaenoate a potential biomarker for the consumption of these food products.

   

Ile-Val-Val

2-({2-[(2-amino-1-hydroxy-3-methylpentylidene)amino]-1-hydroxy-3-methylbutylidene}amino)-3-methylbutanoic acid

C16H31N3O4 (329.2314)


   

Tricalysiamide A

Tricalysiamide A

C20H27NO3 (329.1991)


   
   

2,7-Dihydrohomoerysotrine

2,7-Dihydrohomoerysotrine

C20H27NO3 (329.1991)


   

Morusimic acid D

(-)-Morusimic acid D

C18H35NO4 (329.2566)


   
   

Morusimic acid B

(+)-Morusimic acid B

C18H35NO4 (329.2566)


   

8-Isothiocyanatocycloamphilect-10-ene

8-Isothiocyanatocycloamphilect-10-ene

C21H31NS (329.2177)


   

Norsongorine

N-Deethylsongorine

C20H27NO3 (329.1991)


   
   

Pseudokobusine

Pseudokobusine

C20H27NO3 (329.1991)


   
   
   
   
   

Morusimic acid F

Morusimic acid F

C18H35NO4 (329.2566)


   
   
   

XLR11 Degradant

XLR11 Degradant

C21H28FNO (329.2155)


   
   

Tralkoxydim

Tralkoxydim (isomer2)

C20H27NO3 (329.1991)


   

(-)-7-Hydroxy-10t,11-dimethyl-(4at,7ac,11ac,13at)-Delta6-hexadecahydro-7r,13c-methano-naphtho[2,1:4,5]cyclohepta[1,2-b]pyridin-5-on|(-)-7-hydroxy-10t,11-dimethyl-(4at,7ac,11ac,13at)-Delta6-hexadecahydro-7r,13c-methano-naphtho[2,1:4,5]cyclohepta[1,2-b]pyridin-5-one|Himbadine

(-)-7-Hydroxy-10t,11-dimethyl-(4at,7ac,11ac,13at)-Delta6-hexadecahydro-7r,13c-methano-naphtho[2,1:4,5]cyclohepta[1,2-b]pyridin-5-on|(-)-7-hydroxy-10t,11-dimethyl-(4at,7ac,11ac,13at)-Delta6-hexadecahydro-7r,13c-methano-naphtho[2,1:4,5]cyclohepta[1,2-b]pyridin-5-one|Himbadine

C21H31NO2 (329.2355)


   

Penaresidin A|penaresidins A

Penaresidin A|penaresidins A

C19H39NO3 (329.293)


   

4-Dehydrofuntumafrine B

4-Dehydrofuntumafrine B

C22H35NO (329.2719)


   

pipercallosidine|Pipercallosine

pipercallosidine|Pipercallosine

C20H27NO3 (329.1991)


   

Holadysamine

Holadysamine

C22H35NO (329.2719)


   
   

Penaresidin B

2S-((11S-hydroxy-13-methyltetradecyl)-4S-(hydroxymethyl)azetidin-3R-ol

C19H39NO3 (329.293)


   

Alkaloid PC-II

Alkaloid PC-II

C20H27NO3 (329.1991)


   

(2E,4E,9Z)-octadeca-2,4,9-trien-12-ynoic acid isobutylamine

(2E,4E,9Z)-octadeca-2,4,9-trien-12-ynoic acid isobutylamine

C22H35NO (329.2719)


   
   

3beta-Methylamino-pregn-5-en-20-on|3beta-methylamino-pregn-5-en-20-one|Holaphyllin

3beta-Methylamino-pregn-5-en-20-on|3beta-methylamino-pregn-5-en-20-one|Holaphyllin

C22H35NO (329.2719)


   

(1S,17S)-4,5,17-trimethoxy-11-azatetracyclo[9.7.0.0^{1,14.0^{2,7]octadeca-2,4,6,14-tetraene

(1S,17S)-4,5,17-trimethoxy-11-azatetracyclo[9.7.0.0^{1,14.0^{2,7]octadeca-2,4,6,14-tetraene

C20H27NO3 (329.1991)


   

Monomethylholamine

Monomethylholamine

C22H35NO (329.2719)


   

7alpha-hydroxycossonidine

7alpha-hydroxycossonidine

C20H27NO3 (329.1991)


   

gitingensine

gitingensine

C21H31NO2 (329.2355)


A natural product found in Kibatalia laurifolia.

   
   

9-hydroxynominine

9-hydroxynominine

C20H27NO3 (329.1991)


   

(+)-7-hydroxyamino-octadecanoic acid methyl ester

(+)-7-hydroxyamino-octadecanoic acid methyl ester

C19H39NO3 (329.293)


   

kalihipyran C

kalihipyran C

C21H31NO2 (329.2355)


   
   

N-[(3R,7R)-(+)-jasmonoyl]tyramine

N-[(3R,7R)-(+)-jasmonoyl]tyramine

C20H27NO3 (329.1991)


   

methylamino-3beta oxo-16 pregnene-17(20) E

methylamino-3beta oxo-16 pregnene-17(20) E

C22H35NO (329.2719)


   

2,3,11a-Trimethyl-2,3,3a,4,5,5a,5b,6,8,9,10,11,11a,11b,12,13-hexadecahydro-1H-2-aza-pentaleno[1,6a-a]phenanthren-9-ol

2,3,11a-Trimethyl-2,3,3a,4,5,5a,5b,6,8,9,10,11,11a,11b,12,13-hexadecahydro-1H-2-aza-pentaleno[1,6a-a]phenanthren-9-ol

C22H35NO (329.2719)


   

1-[7-(3,4-methylenedioxyphenyl)-(2E,4E)-heptadienoyl]-N-isobutylamide

1-[7-(3,4-methylenedioxyphenyl)-(2E,4E)-heptadienoyl]-N-isobutylamide

C20H27NO3 (329.1991)


   
   
   
   
   
   
   
   
   
   
   
   

3-[(6-Oxodecanoyl)oxy]-4-(trimethylammonio)butanoate

3-[(6-Oxodecanoyl)oxy]-4-(trimethylammonio)butanoate

C17H31NO5 (329.2202)


   

Trilostane

Trilostane

C20H27NO3 (329.1991)


H - Systemic hormonal preparations, excl. sex hormones and insulins > H02 - Corticosteroids for systemic use > H02C - Antiadrenal preparations > H02CA - Anticorticosteroids C471 - Enzyme Inhibitor > C54678 - Hydroxysteroid Dehydrogenase Inhibitor > C2184 - 3-Hydroxysteroid Dehydrogenase Inhibitor C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C274 - Antineoplastic Agent > C129818 - Antineoplastic Hormonal/Endocrine Agent > C481 - Antiestrogen C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C1740 - Aromatase Inhibitor D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist > C2355 - Anti-Adrenal D012102 - Reproductive Control Agents > D000019 - Abortifacient Agents C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor D000970 - Antineoplastic Agents D004791 - Enzyme Inhibitors CONFIDENCE standard compound; INTERNAL_ID 720; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4414; ORIGINAL_PRECURSOR_SCAN_NO 4413 CONFIDENCE standard compound; INTERNAL_ID 720; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4409; ORIGINAL_PRECURSOR_SCAN_NO 4407 CONFIDENCE standard compound; INTERNAL_ID 720; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4370; ORIGINAL_PRECURSOR_SCAN_NO 4368 CONFIDENCE standard compound; INTERNAL_ID 720; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4405; ORIGINAL_PRECURSOR_SCAN_NO 4404 CONFIDENCE standard compound; INTERNAL_ID 720; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4411; ORIGINAL_PRECURSOR_SCAN_NO 4410 CONFIDENCE standard compound; INTERNAL_ID 720; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4413; ORIGINAL_PRECURSOR_SCAN_NO 4412 CONFIDENCE standard compound; INTERNAL_ID 720; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8763; ORIGINAL_PRECURSOR_SCAN_NO 8759 CONFIDENCE standard compound; INTERNAL_ID 720; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9288; ORIGINAL_PRECURSOR_SCAN_NO 9285 CONFIDENCE standard compound; INTERNAL_ID 720; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9297; ORIGINAL_PRECURSOR_SCAN_NO 9293 CONFIDENCE standard compound; INTERNAL_ID 720; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9341; ORIGINAL_PRECURSOR_SCAN_NO 9336 CONFIDENCE standard compound; INTERNAL_ID 720; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8839; ORIGINAL_PRECURSOR_SCAN_NO 8834 CONFIDENCE standard compound; INTERNAL_ID 720; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8911; ORIGINAL_PRECURSOR_SCAN_NO 8909

   

2-methoxy-phenylacryloyl-lupinine

NCGC00160250-01!2-methoxy-phenylacryloyl-lupinine

C20H27NO3 (329.1991)


   

HETISINE

NCGC00160245-01!HETISINE

C20H27NO3 (329.1991)


   

MLS000728590-01!

MLS000728590-01!

C20H27NO3 (329.1991)


   

(1-(5-Fluoropentyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone

(1-(5-Fluoropentyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone

C21H28FNO (329.2155)


   

prenylamine

prenylamine

C24H27N (329.2143)


C - Cardiovascular system > C01 - Cardiac therapy > C01D - Vasodilators used in cardiac diseases C78274 - Agent Affecting Cardiovascular System > C29707 - Vasodilating Agent D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators

   

Delatine

Delatine

C20H27NO3 (329.1991)


Origin: Plant; Formula(Parent): C20H27NO3; Bottle Name:Hetisine hydrochloride; PRIME Parent Name:Hetisine; PRIME in-house No.:V0348; SubCategory_DNP: Terpenoid alkaloids, Diterpene alkaloid, Aconitum alkaloid

   

Putative (3-hydroxyhexadecanoyl)glycine (aka Commendamide)

Putative (3-hydroxyhexadecanoyl)glycine (aka Commendamide)

C18H35NO4 (329.2566)


   

Decyltyrazolone

Decyltyrazolone

C20H27NO3 (329.1991)


   
   

N-desethyloxybutynin

N-desethyloxybutynin

C20H27NO3 (329.1991)


D000890 - Anti-Infective Agents > D000892 - Anti-Infective Agents, Urinary > D008333 - Mandelic Acids

   
   
   

Penaresidin A

2S-((11S-hydroxy-12-methyltetradecyl)-4S-(hydroxymethyl)azetidin-3R-ol

C19H39NO3 (329.293)


   

4,8 dimethylnonanoyl carnitine

4,8 dimethylnonanoyl carnitine

C18H35NO4 (329.2566)


   

Dihydroceramide

N-[(2S,3R)-1,3-Dihydroxyoctadecan-2-yl]formamide

C19H39NO3 (329.293)


   

Palmitoyl Serinol

N-[2-Hydroxy-1-(hydroxymethyl)ethyl]-hexadecanamide

C19H39NO3 (329.293)


   
   

Retrofractamide C

(2E,8E)-9-(2H-1,3-benzodioxol-5-yl)-N-(2-methylpropyl)nona-2,8-dienamide

C20H27NO3 (329.1991)


   

Tricholein

(8Z)-9-(2H-1,3-benzodioxol-5-yl)-1-(pyrrolidin-1-yl)non-8-en-1-one

C20H27NO3 (329.1991)


   

Pipertipine

(7E)-8-(2H-1,3-benzodioxol-5-yl)-1-(piperidin-1-yl)oct-7-en-1-one

C20H27NO3 (329.1991)


   

CAR 11:0

3-[(4,8-dimethylnonanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C18H35NO4 (329.2566)


   

CAR 10:1;O

3-[(6-oxodecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C17H31NO5 (329.2202)


   

NA 19:0;O2

N-(1,3-dihydroxypropan-2-yl)hexadecanamide

C19H39NO3 (329.293)


   

Bacillamidin A

(1?R)-9-methyldecanoyl dimethylaspartate

C17H31NO5 (329.2202)


   

Commendamide

N-(3-Hydroxyhexadecanoyl) glycine

C18H35NO4 (329.2566)


   

Pipoctanone

Pipoctanone

C22H35NO (329.2719)


   

4-[2-[benzyl(tert-butyl)amino]-1-hydroxyethyl]-2-(hydroxymethyl)phenol

4-[2-[benzyl(tert-butyl)amino]-1-hydroxyethyl]-2-(hydroxymethyl)phenol

C20H27NO3 (329.1991)


   

4-Benzyl Albuterol

4-Benzyl Albuterol

C20H27NO3 (329.1991)


   

1-BOC-4-[2-(1H-INDOL-3-YL)-ETHYL]-PIPERAZINE

1-BOC-4-[2-(1H-INDOL-3-YL)-ETHYL]-PIPERAZINE

C19H27N3O2 (329.2103)


   

Androisoxazole

Androisoxazole

C21H31NO2 (329.2355)


   

Bornaprine

3-(diethylamino)propyl 3-phenylbicyclo[2.2.1]heptane-3-carboxylate

C21H31NO2 (329.2355)


N - Nervous system > N04 - Anti-parkinson drugs > N04A - Anticholinergic agents > N04AA - Tertiary amines D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists

   

Orciprenaline sulfate

Orciprenaline sulfate

C11H17NO3.1/2H2O4S (329.2447)


Metaproterenol hemisulfate (Orciprenaline hemisulfate) is a direct-acting sympathomimetic and a β2-adrenergic receptor (β2AR) agonist with an IC50 of 68 nM. Metaproterenol hemisulfate also has anti-inflammatory activity[1][2].

   

buta-1,3-diene,prop-2-enenitrile,prop-1-en-2-ylbenzene,styrene

buta-1,3-diene,prop-2-enenitrile,prop-1-en-2-ylbenzene,styrene

C24H27N (329.2143)


   
   

L-Glutamic acid,N-(1-oxododecyl)-

L-Glutamic acid,N-(1-oxododecyl)-

C17H31NO5 (329.2202)


   

N-BENZOYLMEROQUINENE TERT-BUTYL ESTER

N-BENZOYLMEROQUINENE TERT-BUTYL ESTER

C20H27NO3 (329.1991)


   

5FUR-144

(1-(5-Fluoropentyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone

C21H28FNO (329.2155)


   

1-ISOTHIOCYANATO-4-(TRANS-4-OCTYLCYCLO-H EXYL)BENZENE

1-ISOTHIOCYANATO-4-(TRANS-4-OCTYLCYCLO-H EXYL)BENZENE

C21H31NS (329.2177)


   

2,6-Bis[(4S)-4-tert-butyloxazolin-2-yl]pyridine

2,6-Bis[(4S)-4-tert-butyloxazolin-2-yl]pyridine

C19H27N3O2 (329.2103)


   

3-[2-carboxyethyl(dodecyl)amino]propanoic acid

3-[2-carboxyethyl(dodecyl)amino]propanoic acid

C18H35NO4 (329.2566)


   
   

Tetrabutylammonium tetrafluoroborate

Tetrabutylammonium tetrafluoroborate

C16H36BF4N (329.2877)


   

2,6-Bis[(4R)-4-tert-butyl-2-oxazolin-2-yl]pyridine

2,6-Bis[(4R)-4-tert-butyl-2-oxazolin-2-yl]pyridine

C19H27N3O2 (329.2103)


   
   

Methanone, (4-​methyl-​1-​piperidinyl)​[3-​(4,​4,​5,​5-​tetramethyl-​1,​3,​2-​dioxaborolan-​2-​yl)​phenyl]​-

Methanone, (4-​methyl-​1-​piperidinyl)​[3-​(4,​4,​5,​5-​tetramethyl-​1,​3,​2-​dioxaborolan-​2-​yl)​phenyl]​-

C19H28BNO3 (329.2162)


   

(R)-De(aminosulfonyl) Tamsulosin

(R)-De(aminosulfonyl) Tamsulosin

C20H27NO3 (329.1991)


   
   

Malachite green cation

Malachite green cation

C23H25N2+ (329.2018)


D004396 - Coloring Agents > D012394 - Rosaniline Dyes D000890 - Anti-Infective Agents D016573 - Agrochemicals D010575 - Pesticides

   

Bavisant

Bavisant

C19H27N3O2 (329.2103)


C78272 - Agent Affecting Nervous System > C47795 - CNS Stimulant Bavisant (JNJ-31001074) is an orally active, potent, brain-penetrating and highly selective antagonist of the histamine H3 receptor. Bavisant can be used for attention-deficit hyperactivity disorder (ADHD) research[1][2][3].

   

((1R,3S)-1-amino-3-((R)-6-hexyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol

((1R,3S)-1-amino-3-((R)-6-hexyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol

C22H35NO (329.2719)


   

2-[(Formyl-hydroxy-amino)-methyl]-hexanoic acid (1-dimethylcarbamoyl-2,2-dimethyl-propyl)-amide

2-[(Formyl-hydroxy-amino)-methyl]-hexanoic acid (1-dimethylcarbamoyl-2,2-dimethyl-propyl)-amide

C16H31N3O4 (329.2314)


   

N-lauroyl-DL-glutamic acid

N-lauroyl-DL-glutamic acid

C17H31NO5 (329.2202)


   

1H-2-Benzopyran-5,6-diol, 1-(aminomethyl)-3,4-dihydro-3-tricyclo(3.3.1.13,7)dec-1-yl-, (1R,3S)-

1H-2-Benzopyran-5,6-diol, 1-(aminomethyl)-3,4-dihydro-3-tricyclo(3.3.1.13,7)dec-1-yl-, (1R,3S)-

C20H27NO3 (329.1991)


D002491 - Central Nervous System Agents > D018726 - Anti-Dyskinesia Agents > D000978 - Antiparkinson Agents D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018491 - Dopamine Agonists

   

XLR11 N-(2-fluoropentyl) isomer

XLR11 N-(2-fluoropentyl) isomer

C21H28FNO (329.2155)


   

Penaresidin

Penaresidin

C19H39NO3 (329.293)


   

(3r)-4-(Trimethylammonio)-3-(undecanoyloxy)butanoate

(3r)-4-(Trimethylammonio)-3-(undecanoyloxy)butanoate

C18H35NO4 (329.2566)


   

L-Valyl-L-valyl-L-isoleucine

L-Valyl-L-valyl-L-isoleucine

C16H31N3O4 (329.2314)


   

Bornaprinum

Bornaprinum

C21H31NO2 (329.2355)


C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists

   

(7Z,10Z,13Z,16Z,19Z)-docosapentaenoate

(7Z,10Z,13Z,16Z,19Z)-docosapentaenoate

C22H33O2- (329.248)


A polyunsaturated fatty acid anion that is the conjugate base of (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

(4Z,7Z,10Z,13Z,16Z)-docosapentaenoate

(4Z,7Z,10Z,13Z,16Z)-docosapentaenoate

C22H33O2- (329.248)


A polyunsaturated fatty acid anion that is the conjugate base of (4Z,7Z,10Z,13Z,16Z)-docosapentaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

(9Z)-12,13,17-trihydroxyoctadeca-9-enoate

(9Z)-12,13,17-trihydroxyoctadeca-9-enoate

C18H33O5- (329.2328)


   

(2E,4E,6E,8E,10E)-docosapentaenoate

(2E,4E,6E,8E,10E)-docosapentaenoate

C22H33O2- (329.248)


   

1-[(8E)-9-(3,4-methylenedioxyphenyl)-8-nonenoyl]pyrrolidine

1-[(8E)-9-(3,4-methylenedioxyphenyl)-8-nonenoyl]pyrrolidine

C20H27NO3 (329.1991)


A natural product found in Piper boehmeriaefolium.

   

3-oxodecanoylcarnitine

3-oxodecanoylcarnitine

C17H31NO5 (329.2202)


   

9-Oxodecanoylcarnitine

9-Oxodecanoylcarnitine

C17H31NO5 (329.2202)


   

7-Oxodecanoylcarnitine

7-Oxodecanoylcarnitine

C17H31NO5 (329.2202)


   

5-Oxodecanoylcarnitine

5-Oxodecanoylcarnitine

C17H31NO5 (329.2202)


   

4-Oxodecanoylcarnitine

4-Oxodecanoylcarnitine

C17H31NO5 (329.2202)


   

8-Oxodecanoylcarnitine

8-Oxodecanoylcarnitine

C17H31NO5 (329.2202)


   

5-Methyldecanoylcarnitine

5-Methyldecanoylcarnitine

C18H35NO4 (329.2566)


   

4-Methyldecanoylcarnitine

4-Methyldecanoylcarnitine

C18H35NO4 (329.2566)


   

6-Methyldecanoylcarnitine

6-Methyldecanoylcarnitine

C18H35NO4 (329.2566)


   

8-Methyldecanoylcarnitine

8-Methyldecanoylcarnitine

C18H35NO4 (329.2566)


   

7-Methyldecanoylcarnitine

7-Methyldecanoylcarnitine

C18H35NO4 (329.2566)


   

3-Methyldecanoylcarnitine

3-Methyldecanoylcarnitine

C18H35NO4 (329.2566)


   

9-Methyldecanoylcarnitine

9-Methyldecanoylcarnitine

C18H35NO4 (329.2566)


   

all-cis-7,10,13,16,19-Docosapentaenoate

all-cis-7,10,13,16,19-Docosapentaenoate

C22H33O2- (329.248)


   

5-Hydroxydec-3-enoylcarnitine

5-Hydroxydec-3-enoylcarnitine

C17H31NO5 (329.2202)


   

5-Hydroxydec-8-enoylcarnitine

5-Hydroxydec-8-enoylcarnitine

C17H31NO5 (329.2202)


   

5-Hydroxydec-5-enoylcarnitine

5-Hydroxydec-5-enoylcarnitine

C17H31NO5 (329.2202)


   

5-Hydroxydec-6-enoylcarnitine

5-Hydroxydec-6-enoylcarnitine

C17H31NO5 (329.2202)


   

5-Hydroxydec-7-enoylcarnitine

5-Hydroxydec-7-enoylcarnitine

C17H31NO5 (329.2202)


   

5-Hydroxydec-4-enoylcarnitine

5-Hydroxydec-4-enoylcarnitine

C17H31NO5 (329.2202)


   

(2Z)-5-Hydroxydec-2-enoylcarnitine

(2Z)-5-Hydroxydec-2-enoylcarnitine

C17H31NO5 (329.2202)


   

Pipercallosine

Pipercallosine

C20H27NO3 (329.1991)


An alkaloid enamide that is (2E,4E)-N-(2-methylpropyl)nona-2,4-dienamide substituted at position 9 by a 1,3-benzodioxol-5-yl group. Isolated from Piper sarmentosum, it has been found to induce apoptosis in HT-29 cells.

   

3-Epi-gitingensine

3-Epi-gitingensine

C21H31NO2 (329.2355)


A natural product found in Kibatalia laurifolia.

   

4-[3-(Dimethylamino)propylamino]-7,8-dimethyl-3-quinolinecarboxylic acid ethyl ester

4-[3-(Dimethylamino)propylamino]-7,8-dimethyl-3-quinolinecarboxylic acid ethyl ester

C19H27N3O2 (329.2103)


   

1-[1-[Oxo(1-pyrrolidinyl)methyl]cyclohexyl]-3-(phenylmethyl)urea

1-[1-[Oxo(1-pyrrolidinyl)methyl]cyclohexyl]-3-(phenylmethyl)urea

C19H27N3O2 (329.2103)


   

(R)-4,8-dimethylnonanoylcarnitine

(R)-4,8-dimethylnonanoylcarnitine

C18H35NO4 (329.2566)


   

2-(3-bicyclo[2.2.1]heptanyl)-1-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethanone

2-(3-bicyclo[2.2.1]heptanyl)-1-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethanone

C20H27NO3 (329.1991)


   
   

4-Methyl-4-aza-5-pregnene-3,20-dione

4-Methyl-4-aza-5-pregnene-3,20-dione

C21H31NO2 (329.2355)


   
   
   
   
   

N-hexadecanoyl-(2S)-hydroxyglycine

N-hexadecanoyl-(2S)-hydroxyglycine

C18H35NO4 (329.2566)


   

N-acyl-1-deoxyphytosphingosine

N-acyl-1-deoxyphytosphingosine

C19H39NO3 (329.293)


   

N-Piperoyl-N,N-dibutylamine

N-Piperoyl-N,N-dibutylamine

C20H27NO3 (329.1991)


   

Psedokobusine

Psedokobusine

C20H27NO3 (329.1991)


   

[(1R,9aR)-2,3,4,6,7,8,9,9a-octahydro-1H-quinolizin-1-yl]methyl (Z)-3-(2-methoxyphenyl)prop-2-enoate

[(1R,9aR)-2,3,4,6,7,8,9,9a-octahydro-1H-quinolizin-1-yl]methyl (Z)-3-(2-methoxyphenyl)prop-2-enoate

C20H27NO3 (329.1991)


   

N-(1,3-dihydroxyheptadecan-2-yl)acetamide

N-(1,3-dihydroxyheptadecan-2-yl)acetamide

C19H39NO3 (329.293)


   

N-(1,3-dihydroxytridecan-2-yl)hexanamide

N-(1,3-dihydroxytridecan-2-yl)hexanamide

C19H39NO3 (329.293)


   

N-(1,3-dihydroxydodecan-2-yl)heptanamide

N-(1,3-dihydroxydodecan-2-yl)heptanamide

C19H39NO3 (329.293)


   

N-(1,3-dihydroxypentadecan-2-yl)butanamide

N-(1,3-dihydroxypentadecan-2-yl)butanamide

C19H39NO3 (329.293)


   

N-(1,3-dihydroxydecan-2-yl)nonanamide

N-(1,3-dihydroxydecan-2-yl)nonanamide

C19H39NO3 (329.293)


   

N-(1,3-dihydroxyundecan-2-yl)octanamide

N-(1,3-dihydroxyundecan-2-yl)octanamide

C19H39NO3 (329.293)


   

N-(1,3-dihydroxyoctan-2-yl)undecanamide

N-(1,3-dihydroxyoctan-2-yl)undecanamide

C19H39NO3 (329.293)


   

N-(1,3-dihydroxytetradecan-2-yl)pentanamide

N-(1,3-dihydroxytetradecan-2-yl)pentanamide

C19H39NO3 (329.293)


   

N-(1,3-dihydroxynonan-2-yl)decanamide

N-(1,3-dihydroxynonan-2-yl)decanamide

C19H39NO3 (329.293)


   

N-(1,3-dihydroxyhexadecan-2-yl)propanamide

N-(1,3-dihydroxyhexadecan-2-yl)propanamide

C19H39NO3 (329.293)


   

(1S,3S,5R,8R,9R,10R,11R,14R,16R,19S)-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.01,8.05,17.07,16.09,14.014,18]nonadecane-3,10,19-triol

(1S,3S,5R,8R,9R,10R,11R,14R,16R,19S)-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.01,8.05,17.07,16.09,14.014,18]nonadecane-3,10,19-triol

C20H27NO3 (329.1991)


   

(1R,2R,6R,8S,11S,12S,15R,16S)-5,15-dihydroxy-2,16-dimethyl-7-oxapentacyclo[9.7.0.02,8.06,8.012,16]octadec-4-ene-4-carbonitrile

(1R,2R,6R,8S,11S,12S,15R,16S)-5,15-dihydroxy-2,16-dimethyl-7-oxapentacyclo[9.7.0.02,8.06,8.012,16]octadec-4-ene-4-carbonitrile

C20H27NO3 (329.1991)


   

(2S)-2-[4-(1-Ethoxyethoxy)-1-oxobutyl]pyrrolidine-1-carboxylic acid tert-butyl ester

(2S)-2-[4-(1-Ethoxyethoxy)-1-oxobutyl]pyrrolidine-1-carboxylic acid tert-butyl ester

C17H31NO5 (329.2202)


   

(1S,3S,5R,8R,10R,11R,14R,16R,19S)-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.01,8.05,17.07,16.09,14.014,18]nonadecane-3,10,19-triol

(1S,3S,5R,8R,10R,11R,14R,16R,19S)-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.01,8.05,17.07,16.09,14.014,18]nonadecane-3,10,19-triol

C20H27NO3 (329.1991)


   

(1S,3S,5R,8R,9R,10R,11R,14R,16R,17R,19S)-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.01,8.05,17.07,16.09,14.014,18]nonadecane-3,10,19-triol

(1S,3S,5R,8R,9R,10R,11R,14R,16R,17R,19S)-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.01,8.05,17.07,16.09,14.014,18]nonadecane-3,10,19-triol

C20H27NO3 (329.1991)


   

Jamine

Homoormosanine

C21H35N3 (329.2831)


   

Delatine (Hetisine)

Delatine (Hetisine)

C20H27NO3 (329.1991)


   

Undecanoylcarnitine

Undecanoylcarnitine

C18H35NO4 (329.2566)


   

6-Keto-decanoylcarnitine

6-Keto-decanoylcarnitine

C17H31NO5 (329.2202)


   

(8E)-Piperamide-C9:1

(8E)-Piperamide-C9:1

C20H27NO3 (329.1991)


   

Docosapentaenoate

Docosapentaenoate

C22H33O2 (329.248)


A polyunsaturated fatty acid anion that is the conjugate base of docosapentaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

[1-(5-Fluoropentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone

[1-(5-Fluoropentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone

C21H28FNO (329.2155)


   
   
   
   

NA-Cys 14:1(9Z)

NA-Cys 14:1(9Z)

C17H31NO3S (329.2025)


   
   
   
   

CAR 10:0;6oxo

CAR 10:0;6oxo

C17H31NO5 (329.2202)


   
   
   

Cer 8:0;O2/11:0

Cer 8:0;O2/11:0

C19H39NO3 (329.293)


   

5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-3,15,19-triol

5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-3,15,19-triol

C20H27NO3 (329.1991)


   

5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-8,13,19-triol

5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-8,13,19-triol

C20H27NO3 (329.1991)


   

(1s,3s,5r,8r,9s,10r,11r,14r,16s,17r,18r,19s)-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-3,10,19-triol

(1s,3s,5r,8r,9s,10r,11r,14r,16s,17r,18r,19s)-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-3,10,19-triol

C20H27NO3 (329.1991)


   

(2e,4e,8e,10e,14e)-n-(2-methylpropyl)octadeca-2,4,8,10,14-pentaenimidic acid

(2e,4e,8e,10e,14e)-n-(2-methylpropyl)octadeca-2,4,8,10,14-pentaenimidic acid

C22H35NO (329.2719)


   

(1s,2r,5r,8r,9s,11r,13r,14r,15s,16r,17r,18s)-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-2,13,15-triol

(1s,2r,5r,8r,9s,11r,13r,14r,15s,16r,17r,18s)-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-2,13,15-triol

C20H27NO3 (329.1991)


   

4,5,17-trimethoxy-11-azatetracyclo[9.7.0.0¹,¹⁴.0²,⁷]octadeca-2(7),3,5,15-tetraene

4,5,17-trimethoxy-11-azatetracyclo[9.7.0.0¹,¹⁴.0²,⁷]octadeca-2(7),3,5,15-tetraene

C20H27NO3 (329.1991)


   

(1s,17r)-4,5,17-trimethoxy-11-azatetracyclo[9.7.0.0¹,¹⁴.0²,⁷]octadeca-2(7),3,5,14-tetraene

(1s,17r)-4,5,17-trimethoxy-11-azatetracyclo[9.7.0.0¹,¹⁴.0²,⁷]octadeca-2(7),3,5,14-tetraene

C20H27NO3 (329.1991)


   

(1s,3ar,3a¹s,4s,5as,5a¹s,10as)-10a-isothiocyanato-1,4,7,7-tetramethyl-1,2,3,3a,3a¹,4,5,5a,5a¹,6,8,10-dodecahydropyrene

(1s,3ar,3a¹s,4s,5as,5a¹s,10as)-10a-isothiocyanato-1,4,7,7-tetramethyl-1,2,3,3a,3a¹,4,5,5a,5a¹,6,8,10-dodecahydropyrene

C21H31NS (329.2177)


   

3-epimethylschelhammericine b

NA

C20H27NO3 (329.1991)


{"Ingredient_id": "HBIN008489","Ingredient_name": "3-epimethylschelhammericine b","Alias": "NA","Ingredient_formula": "C20H27NO3","Ingredient_Smile": "Not Available","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "6968","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

   

3-vinyl-1,2- dimethyl-1,4-cyclohexadiene

NA

C20H27NO3 (329.1991)


{"Ingredient_id": "HBIN009754","Ingredient_name": "3-vinyl-1,2- dimethyl-1,4-cyclohexadiene","Alias": "NA","Ingredient_formula": "C20H27NO3","Ingredient_Smile": "CC1(COC(=N1)C2=CC=C(C(C2C=C)(C)C(=O)CCC=C)OC)C","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "42372","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

   

9-(2h-1,3-benzodioxol-5-yl)-n-(2-methylpropyl)nona-2,4-dienimidic acid

9-(2h-1,3-benzodioxol-5-yl)-n-(2-methylpropyl)nona-2,4-dienimidic acid

C20H27NO3 (329.1991)


   

mycalenitrile-19

mycalenitrile-19

C22H35NO (329.2719)


   

(1r,2r,13s,15r,16r,23r)-7,9,21-triazahexacyclo[11.9.1.1¹,¹⁵.0²,⁷.0⁹,²³.0¹⁶,²¹]tetracosane

(1r,2r,13s,15r,16r,23r)-7,9,21-triazahexacyclo[11.9.1.1¹,¹⁵.0²,⁷.0⁹,²³.0¹⁶,²¹]tetracosane

C21H35N3 (329.2831)


   

n-[2-(4-hydroxyphenyl)ethyl]-2-[(1r,2r)-3-oxo-2-[(2z)-pent-2-en-1-yl]cyclopentyl]ethanimidic acid

n-[2-(4-hydroxyphenyl)ethyl]-2-[(1r,2r)-3-oxo-2-[(2z)-pent-2-en-1-yl]cyclopentyl]ethanimidic acid

C20H27NO3 (329.1991)


   

(1s,4s,12s,13s,16r,17r)-17-(hydroxymethyl)-12-methyl-8-azapentacyclo[14.2.1.0¹,¹³.0⁴,¹².0⁵,⁹]nonadeca-5,7,9-triene-7,17-diol

(1s,4s,12s,13s,16r,17r)-17-(hydroxymethyl)-12-methyl-8-azapentacyclo[14.2.1.0¹,¹³.0⁴,¹².0⁵,⁹]nonadeca-5,7,9-triene-7,17-diol

C20H27NO3 (329.1991)


   

(3r)-3-hydroxy-12-[(2r,5s,6s)-5-hydroxy-6-methylpiperidin-2-yl]dodecanoic acid

(3r)-3-hydroxy-12-[(2r,5s,6s)-5-hydroxy-6-methylpiperidin-2-yl]dodecanoic acid

C18H35NO4 (329.2566)


   

(1s,14s,17r)-4,5,17-trimethoxy-11-azatetracyclo[9.7.0.0¹,¹⁴.0²,⁷]octadeca-2(7),3,5,15-tetraene

(1s,14s,17r)-4,5,17-trimethoxy-11-azatetracyclo[9.7.0.0¹,¹⁴.0²,⁷]octadeca-2(7),3,5,15-tetraene

C20H27NO3 (329.1991)


   

n-(2-methylpropyl)octadeca-2,4,9-trien-12-ynimidic acid

n-(2-methylpropyl)octadeca-2,4,9-trien-12-ynimidic acid

C22H35NO (329.2719)


   

9-(2h-1,3-benzodioxol-5-yl)-1-(pyrrolidin-1-yl)non-8-en-1-one

9-(2h-1,3-benzodioxol-5-yl)-1-(pyrrolidin-1-yl)non-8-en-1-one

C20H27NO3 (329.1991)


   

(1r,3s,5r,8r,9s,10s,11s,14r,16r,17r,18r)-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-3,10,16-triol

(1r,3s,5r,8r,9s,10s,11s,14r,16r,17r,18r)-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-3,10,16-triol

C20H27NO3 (329.1991)


   

(1s,3s,5s,8r,9s,11r,14r,16s,17r,18r,19s)-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-3,10,19-triol

(1s,3s,5s,8r,9s,11r,14r,16s,17r,18r,19s)-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-3,10,19-triol

C20H27NO3 (329.1991)


   

(1r,5r,8r,9s,10r,11s,13r,14s,16r,17r,18s)-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-10,13,16-triol

(1r,5r,8r,9s,10r,11s,13r,14s,16r,17r,18s)-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-10,13,16-triol

C20H27NO3 (329.1991)


   

(1r,2r,13r,15s,16s,23s)-7,9,21-triazahexacyclo[11.9.1.1¹,¹⁵.0²,⁷.0⁹,²³.0¹⁶,²¹]tetracosane

(1r,2r,13r,15s,16s,23s)-7,9,21-triazahexacyclo[11.9.1.1¹,¹⁵.0²,⁷.0⁹,²³.0¹⁶,²¹]tetracosane

C21H35N3 (329.2831)


   

5-hydroxy-3,15,17,17-tetramethyl-7-methylidene-15-azatricyclo[8.5.2.0¹³,¹⁶]heptadeca-3,13(16)-dien-14-one

5-hydroxy-3,15,17,17-tetramethyl-7-methylidene-15-azatricyclo[8.5.2.0¹³,¹⁶]heptadeca-3,13(16)-dien-14-one

C21H31NO2 (329.2355)


   

(2e,4e)-9-(2h-1,3-benzodioxol-5-yl)-n-(2-methylpropyl)nona-2,4-dienimidic acid

(2e,4e)-9-(2h-1,3-benzodioxol-5-yl)-n-(2-methylpropyl)nona-2,4-dienimidic acid

C20H27NO3 (329.1991)


   

(1r,2r,13s,15r,16r,23s)-7,9,21-triazahexacyclo[11.9.1.1¹,¹⁵.0²,⁷.0⁹,²³.0¹⁶,²¹]tetracosane

(1r,2r,13s,15r,16r,23s)-7,9,21-triazahexacyclo[11.9.1.1¹,¹⁵.0²,⁷.0⁹,²³.0¹⁶,²¹]tetracosane

C21H35N3 (329.2831)


   

(1r,2s,5r,7r,8r,9r,10s,13r,16s,17r)-7,16-dihydroxy-13-methyl-6-methylidene-11-azahexacyclo[7.7.2.1⁵,⁸.0¹,¹⁰.0²,⁸.0¹³,¹⁷]nonadecan-4-one

(1r,2s,5r,7r,8r,9r,10s,13r,16s,17r)-7,16-dihydroxy-13-methyl-6-methylidene-11-azahexacyclo[7.7.2.1⁵,⁸.0¹,¹⁰.0²,⁸.0¹³,¹⁷]nonadecan-4-one

C20H27NO3 (329.1991)


   

(1r,3e,5s,10r)-5-hydroxy-3,15,17,17-tetramethyl-7-methylidene-15-azatricyclo[8.5.2.0¹³,¹⁶]heptadeca-3,13(16)-dien-14-one

(1r,3e,5s,10r)-5-hydroxy-3,15,17,17-tetramethyl-7-methylidene-15-azatricyclo[8.5.2.0¹³,¹⁶]heptadeca-3,13(16)-dien-14-one

C21H31NO2 (329.2355)


   

8-(2h-1,3-benzodioxol-5-yl)-n-(3-methylbutyl)octa-2,4-dienimidic acid

8-(2h-1,3-benzodioxol-5-yl)-n-(3-methylbutyl)octa-2,4-dienimidic acid

C20H27NO3 (329.1991)


   

(2e,4e)-8-(2h-1,3-benzodioxol-5-yl)-n-(3-methylbutyl)octa-2,4-dienimidic acid

(2e,4e)-8-(2h-1,3-benzodioxol-5-yl)-n-(3-methylbutyl)octa-2,4-dienimidic acid

C20H27NO3 (329.1991)


   

(1s,5r,8r,9s,10s,11r,14r,15s,16r,17r,18s,19s)-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-10,15,19-triol

(1s,5r,8r,9s,10s,11r,14r,15s,16r,17r,18s,19s)-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-10,15,19-triol

C20H27NO3 (329.1991)


   

n-[2-(4-hydroxyphenyl)ethyl]-2-[3-oxo-2-(pent-2-en-1-yl)cyclopentyl]ethanimidic acid

n-[2-(4-hydroxyphenyl)ethyl]-2-[3-oxo-2-(pent-2-en-1-yl)cyclopentyl]ethanimidic acid

C20H27NO3 (329.1991)


   

(1s,3s,5r,8r,9s,10s,11r,14r,16s,17r,18r,19s)-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-3,10,19-triol

(1s,3s,5r,8r,9s,10s,11r,14r,16s,17r,18r,19s)-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-3,10,19-triol

C20H27NO3 (329.1991)


   

5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-2,13,15-triol

5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-2,13,15-triol

C20H27NO3 (329.1991)


   

(1r,3s,5s,8r,9s,11s,13r,14s,16s,17r,18r)-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-3,13,18-triol

(1r,3s,5s,8r,9s,11s,13r,14s,16s,17r,18r)-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-3,13,18-triol

C20H27NO3 (329.1991)


   

(1r,5s,8r,9s,11s,13r,14s,16r,17r,18s)-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-10,13,16-triol

(1r,5s,8r,9s,11s,13r,14s,16r,17r,18s)-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-10,13,16-triol

C20H27NO3 (329.1991)


   

7,16-dihydroxy-13-methyl-6-methylidene-11-azahexacyclo[7.7.2.1⁵,⁸.0¹,¹⁰.0²,⁸.0¹³,¹⁷]nonadecan-4-one

7,16-dihydroxy-13-methyl-6-methylidene-11-azahexacyclo[7.7.2.1⁵,⁸.0¹,¹⁰.0²,⁸.0¹³,¹⁷]nonadecan-4-one

C20H27NO3 (329.1991)


   

n-(2-methylpropyl)octadeca-2,4,8,10,14-pentaenimidic acid

n-(2-methylpropyl)octadeca-2,4,8,10,14-pentaenimidic acid

C22H35NO (329.2719)


   

(1s,5r,8r,9s,10r,11r,13r,14s,16s,17r,18s,19s)-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-10,13,19-triol

(1s,5r,8r,9s,10r,11r,13r,14s,16s,17r,18s,19s)-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-10,13,19-triol

C20H27NO3 (329.1991)


   

4,4-dimethyl-11-(3-methylbut-2-en-1-yl)-12-methylidene-5-oxa-8-azatetracyclo[11.2.1.0¹,¹⁰.0²,⁸]hexadecane

4,4-dimethyl-11-(3-methylbut-2-en-1-yl)-12-methylidene-5-oxa-8-azatetracyclo[11.2.1.0¹,¹⁰.0²,⁸]hexadecane

C22H35NO (329.2719)


   

5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-10,15,19-triol

5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-10,15,19-triol

C20H27NO3 (329.1991)


   

9-(2h-1,3-benzodioxol-5-yl)-n-(2-methylpropyl)nona-2,8-dienimidic acid

9-(2h-1,3-benzodioxol-5-yl)-n-(2-methylpropyl)nona-2,8-dienimidic acid

C20H27NO3 (329.1991)


   

17-(hydroxymethyl)-12-methyl-8-azapentacyclo[14.2.1.0¹,¹³.0⁴,¹².0⁵,⁹]nonadeca-5,7,9-triene-7,17-diol

17-(hydroxymethyl)-12-methyl-8-azapentacyclo[14.2.1.0¹,¹³.0⁴,¹².0⁵,⁹]nonadeca-5,7,9-triene-7,17-diol

C20H27NO3 (329.1991)


   

(1r,5s,8r,9s,11r,13r,14r,16r,17r,18s,19s)-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-13,16,19-triol

(1r,5s,8r,9s,11r,13r,14r,16r,17r,18s,19s)-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-13,16,19-triol

C20H27NO3 (329.1991)


   

(1s,2s,10r,11r,13s)-4,4-dimethyl-11-(3-methylbut-2-en-1-yl)-12-methylidene-5-oxa-8-azatetracyclo[11.2.1.0¹,¹⁰.0²,⁸]hexadecane

(1s,2s,10r,11r,13s)-4,4-dimethyl-11-(3-methylbut-2-en-1-yl)-12-methylidene-5-oxa-8-azatetracyclo[11.2.1.0¹,¹⁰.0²,⁸]hexadecane

C22H35NO (329.2719)


   

(1r,2r,13s,16s,23r)-7,9,21-triazahexacyclo[11.9.1.1¹,¹⁵.0²,⁷.0⁹,²³.0¹⁶,²¹]tetracosane

(1r,2r,13s,16s,23r)-7,9,21-triazahexacyclo[11.9.1.1¹,¹⁵.0²,⁷.0⁹,²³.0¹⁶,²¹]tetracosane

C21H35N3 (329.2831)


   

(1s,5r,8s,9s,11r,13r,14s,16s,17r,18r,19s)-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-8,13,19-triol

(1s,5r,8s,9s,11r,13r,14s,16s,17r,18r,19s)-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-8,13,19-triol

C20H27NO3 (329.1991)


   

(1s,3s,5r,8r,9s,10r,11r,14r,16s,17r,18s,19s)-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-3,10,19-triol

(1s,3s,5r,8r,9s,10r,11r,14r,16s,17r,18s,19s)-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-3,10,19-triol

C20H27NO3 (329.1991)


   

n-(1,4-dimethoxy-1,4-dioxobutan-2-yl)-9-methyldecanimidic acid

n-(1,4-dimethoxy-1,4-dioxobutan-2-yl)-9-methyldecanimidic acid

C17H31NO5 (329.2202)


   

(1s,5r,8r,9s,10s,11r,14s,17r,18r,19s)-10,19-dihydroxy-5-methyl-12-methylidene-7-azahexacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-3-one

(1s,5r,8r,9s,10s,11r,14s,17r,18r,19s)-10,19-dihydroxy-5-methyl-12-methylidene-7-azahexacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-3-one

C20H27NO3 (329.1991)


   

(1s,5s,8s,9s,11r,13r,14s,16s,17r,18r,19s)-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-8,13,19-triol

(1s,5s,8s,9s,11r,13r,14s,16s,17r,18r,19s)-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-8,13,19-triol

C20H27NO3 (329.1991)


   

10,19-dihydroxy-5-methyl-12-methylidene-7-azahexacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-3-one

10,19-dihydroxy-5-methyl-12-methylidene-7-azahexacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-3-one

C20H27NO3 (329.1991)


   

(3ar,3bs,6s,6ar,7s,9as,11as)-7,8-dimethyl-6-(2-methylpropyl)-1h,6h,6ah,7h,9ah,10h,11h,11ah-indeno[5,4-d]isoindole-3a,4-diol

(3ar,3bs,6s,6ar,7s,9as,11as)-7,8-dimethyl-6-(2-methylpropyl)-1h,6h,6ah,7h,9ah,10h,11h,11ah-indeno[5,4-d]isoindole-3a,4-diol

C21H31NO2 (329.2355)


   

(1s,5s,6s,8r,9s,11r,13r,14r,16s,17s,18s,19s)-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-6,13,19-triol

(1s,5s,6s,8r,9s,11r,13r,14r,16s,17s,18s,19s)-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-6,13,19-triol

C20H27NO3 (329.1991)


   

(3r)-3-hydroxy-12-[(2r,5r,6s)-5-hydroxy-6-methylpiperidin-2-yl]dodecanoic acid

(3r)-3-hydroxy-12-[(2r,5r,6s)-5-hydroxy-6-methylpiperidin-2-yl]dodecanoic acid

C18H35NO4 (329.2566)


   

n-[(2r)-1,4-dimethoxy-1,4-dioxobutan-2-yl]-9-methyldecanimidic acid

n-[(2r)-1,4-dimethoxy-1,4-dioxobutan-2-yl]-9-methyldecanimidic acid

C17H31NO5 (329.2202)


   

4,5,17-trimethoxy-11-azatetracyclo[9.7.0.0¹,¹⁴.0²,⁷]octadeca-2(7),3,5,14-tetraene

4,5,17-trimethoxy-11-azatetracyclo[9.7.0.0¹,¹⁴.0²,⁷]octadeca-2(7),3,5,14-tetraene

C20H27NO3 (329.1991)


   

(2e,4e,9z)-n-(2-methylpropyl)octadeca-2,4,9-trien-12-ynimidic acid

(2e,4e,9z)-n-(2-methylpropyl)octadeca-2,4,9-trien-12-ynimidic acid

C22H35NO (329.2719)


   

7,8-dimethyl-6-(2-methylpropyl)-1h,6h,6ah,7h,9ah,10h,11h,11ah-indeno[5,4-d]isoindole-3a,4-diol

7,8-dimethyl-6-(2-methylpropyl)-1h,6h,6ah,7h,9ah,10h,11h,11ah-indeno[5,4-d]isoindole-3a,4-diol

C21H31NO2 (329.2355)


   

3-hydroxy-12-[5-(1-hydroxyethyl)pyrrolidin-2-yl]dodecanoic acid

3-hydroxy-12-[5-(1-hydroxyethyl)pyrrolidin-2-yl]dodecanoic acid

C18H35NO4 (329.2566)


   

(1s,5s,13s,16r,17s,18r,19r)-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-13,16,19-triol

(1s,5s,13s,16r,17s,18r,19r)-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-13,16,19-triol

C20H27NO3 (329.1991)


   

5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-3,10,19-triol

5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-3,10,19-triol

C20H27NO3 (329.1991)


   

5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-3,13,18-triol

5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-3,13,18-triol

C20H27NO3 (329.1991)


   

(1s,4s,12s,13r,16r,17r)-17-(hydroxymethyl)-12-methyl-8-azapentacyclo[14.2.1.0¹,¹³.0⁴,¹².0⁵,⁹]nonadeca-5,7,9-triene-7,17-diol

(1s,4s,12s,13r,16r,17r)-17-(hydroxymethyl)-12-methyl-8-azapentacyclo[14.2.1.0¹,¹³.0⁴,¹².0⁵,⁹]nonadeca-5,7,9-triene-7,17-diol

C20H27NO3 (329.1991)


   

(3r)-3-hydroxy-12-[(2s,5s)-5-[(1s)-1-hydroxyethyl]pyrrolidin-2-yl]dodecanoic acid

(3r)-3-hydroxy-12-[(2s,5s)-5-[(1s)-1-hydroxyethyl]pyrrolidin-2-yl]dodecanoic acid

C18H35NO4 (329.2566)


   

5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-3,10,16-triol

5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-3,10,16-triol

C20H27NO3 (329.1991)


   

(1r,2r,5r,7r,8r,9r,10s,13r,16s,17r)-7,16-dihydroxy-13-methyl-6-methylidene-11-azahexacyclo[7.7.2.1⁵,⁸.0¹,¹⁰.0²,⁸.0¹³,¹⁷]nonadecan-4-one

(1r,2r,5r,7r,8r,9r,10s,13r,16s,17r)-7,16-dihydroxy-13-methyl-6-methylidene-11-azahexacyclo[7.7.2.1⁵,⁸.0¹,¹⁰.0²,⁸.0¹³,¹⁷]nonadecan-4-one

C20H27NO3 (329.1991)


   

(1r,2r,13s,15s,16r,23r)-7,9,21-triazahexacyclo[11.9.1.1¹,¹⁵.0²,⁷.0⁹,²³.0¹⁶,²¹]tetracosane

(1r,2r,13s,15s,16r,23r)-7,9,21-triazahexacyclo[11.9.1.1¹,¹⁵.0²,⁷.0⁹,²³.0¹⁶,²¹]tetracosane

C21H35N3 (329.2831)


   

(1s,17s)-4,5,17-trimethoxy-11-azatetracyclo[9.7.0.0¹,¹⁴.0²,⁷]octadeca-2(7),3,5,14-tetraene

(1s,17s)-4,5,17-trimethoxy-11-azatetracyclo[9.7.0.0¹,¹⁴.0²,⁷]octadeca-2(7),3,5,14-tetraene

C20H27NO3 (329.1991)


   

(1s,2r,5s,8r,9s,11r,13r,14r,15r,16r,17r,18s)-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-2,13,15-triol

(1s,2r,5s,8r,9s,11r,13r,14r,15r,16r,17r,18s)-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-2,13,15-triol

C20H27NO3 (329.1991)


   

n-[(1r,4r,4as,8ar)-1,6-dimethyl-4-[6-(prop-1-en-2-yl)-5,6-dihydro-2h-pyran-3-yl]-3,4,4a,7,8,8a-hexahydro-2h-naphthalen-1-yl]carboximidic acid

n-[(1r,4r,4as,8ar)-1,6-dimethyl-4-[6-(prop-1-en-2-yl)-5,6-dihydro-2h-pyran-3-yl]-3,4,4a,7,8,8a-hexahydro-2h-naphthalen-1-yl]carboximidic acid

C21H31NO2 (329.2355)


   

7,9,21-triazahexacyclo[11.9.1.1¹,¹⁵.0²,⁷.0⁹,²³.0¹⁶,²¹]tetracosane

7,9,21-triazahexacyclo[11.9.1.1¹,¹⁵.0²,⁷.0⁹,²³.0¹⁶,²¹]tetracosane

C21H35N3 (329.2831)


   

3-hydroxy-12-(5-hydroxy-6-methylpiperidin-2-yl)dodecanoic acid

3-hydroxy-12-(5-hydroxy-6-methylpiperidin-2-yl)dodecanoic acid

C18H35NO4 (329.2566)


   

(2e,8e)-9-(2h-1,3-benzodioxol-5-yl)-n-(2-methylpropyl)nona-2,8-dienimidic acid

(2e,8e)-9-(2h-1,3-benzodioxol-5-yl)-n-(2-methylpropyl)nona-2,8-dienimidic acid

C20H27NO3 (329.1991)


   

8-(2h-1,3-benzodioxol-5-yl)-1-(piperidin-1-yl)oct-7-en-1-one

8-(2h-1,3-benzodioxol-5-yl)-1-(piperidin-1-yl)oct-7-en-1-one

C20H27NO3 (329.1991)


   

(1r,2s,13r,15s,16r,23s)-7,9,21-triazahexacyclo[11.9.1.1¹,¹⁵.0²,⁷.0⁹,²³.0¹⁶,²¹]tetracosane

(1r,2s,13r,15s,16r,23s)-7,9,21-triazahexacyclo[11.9.1.1¹,¹⁵.0²,⁷.0⁹,²³.0¹⁶,²¹]tetracosane

C21H35N3 (329.2831)